- Home
- CHI vs COLL Comparison
CHI vs COLL Comparison
Compare CHI & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- COLL
- Stock Information
- Founded
- CHI 2002
- COLL 2002
- Country
- CHI United States
- COLL United States
- Employees
- CHI N/A
- COLL N/A
- Industry
- CHI Investment Managers
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- CHI Finance
- COLL Health Care
- Exchange
- CHI Nasdaq
- COLL Nasdaq
- Market Cap
- CHI 879.5M
- COLL 1.1B
- IPO Year
- CHI N/A
- COLL 2015
- Fundamental
- Price
- CHI $12.04
- COLL $30.41
- Analyst Decision
- CHI
- COLL Strong Buy
- Analyst Count
- CHI 0
- COLL 6
- Target Price
- CHI N/A
- COLL $42.00
- AVG Volume (30 Days)
- CHI 186.2K
- COLL 462.1K
- Earning Date
- CHI 01-01-0001
- COLL 11-07-2024
- Dividend Yield
- CHI 9.90%
- COLL N/A
- EPS Growth
- CHI N/A
- COLL 757.11
- EPS
- CHI N/A
- COLL 2.16
- Revenue
- CHI N/A
- COLL $599,245,000.00
- Revenue This Year
- CHI N/A
- COLL $13.02
- Revenue Next Year
- CHI N/A
- COLL $18.01
- P/E Ratio
- CHI N/A
- COLL $13.87
- Revenue Growth
- CHI N/A
- COLL 9.62
- 52 Week Low
- CHI $9.70
- COLL $25.16
- 52 Week High
- CHI $11.61
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- CHI 59.96
- COLL 34.91
- Support Level
- CHI $11.60
- COLL $28.97
- Resistance Level
- CHI $12.08
- COLL $35.62
- Average True Range (ATR)
- CHI 0.17
- COLL 1.37
- MACD
- CHI 0.03
- COLL -0.13
- Stochastic Oscillator
- CHI 87.26
- COLL 21.65
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.